Supportive care medications coinciding with chemotherapy among children with hematologic malignancy

References

• Siegel DA, Li J, Henley SJ, et al. Geographic variation in pediatric cancer incidence – United States, 2003-2014. MMWR Morb Mortal Wkly Rep. 2018;67:707–713.
   PubMed Web of Science ®Google Scholar
• Gedik H, Simsek F, Kanturk A, et al. Bloodstream infections in patients with hematological malignancies: which is more fatal - cancer or resistant pathogens? Ther Clin Risk Manag. 2014;10:743–752.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol. 2017;35:2082–2094.
   PubMed Web of Science ®Google Scholar
• Salstrom JL, Coughlin RL, Pool K, et al. Pediatric patients who receive antibiotics for fever and neutropenia in less than 60 min have decreased intensive care needs. Pediatr Blood Cancer. 2015;62:807–815.
   PubMed Web of Science ®Google Scholar
• Feinstein J, Dai D, Zhong W, et al. Potential drug-drug interactions in infant, child, and adolescent patients in children’s hospitals. Pediatrics. 2015;135:e99–108.
   PubMed Web of Science ®Google Scholar
• Fisher BT, Gerber JS, Leckerman KH, et al. Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia. Leuk Lymphoma. 2013;54:1633–1639.
   PubMed Web of Science ®Google Scholar
• Dai D, Feinstein JA, Morrison W, et al. Epidemiology of polypharmacy and potential drug-drug interactions among pediatric patients in ICUs of U.S. children’s hospitals. Pediatr Crit Care Med. 2016;17:e218–228.
   PubMed Web of Science ®Google Scholar
• Marcath LA, Coe TD, Hoylman EK, et al. Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials. BMC Cancer. 2018;18:1155.
   PubMed Web of Science ®Google Scholar
• Thiesen S, Conroy EJ, Bellis JR, et al. Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children - a prospective observational cohort study of 6,601 admissions. BMC Med. 2013;11:237.
   PubMed Web of Science ®Google Scholar
• Arnott J, Hesselgreaves H, Nunn AJ, et al. Enhancing communication about paediatric medicines: lessons from a qualitative study of parents’ experiences of their child’s suspected adverse drug reaction. PLoS One. 2012;7:e46022.
   PubMed Web of Science ®Google Scholar
• Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005;5:447–458.
   PubMed Web of Science ®Google Scholar
• Harvey RD, Morgan ET. Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther. 2014;96:449–457.
   PubMed Web of Science ®Google Scholar
• Marsot A, Gallais F, Galambrun C, et al. Vancomycin in pediatric patients with solid or hematological malignant disease: predictive performance of a population pharmacokinetic model and new optimized dosing regimens. Pediatr Drugs. 2018;20:375–381.
   PubMed Web of Science ®Google Scholar
• Balch AH, Constance JE, Thorell EA, et al. Pediatric vancomycin dosing: trends over time and the impact of therapeutic drug monitoring. J Clin Pharmacol. 2015;55:212–220.
   PubMed Web of Science ®Google Scholar
• Yang L, Panetta JC, Cai X, et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol. 2008;26:1932–1939.
   PubMed Web of Science ®Google Scholar
• Conyers R, Devaraja S, Elliott D. Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients. Pediatr Blood Cancer. 2018;65:e26937.
   Web of Science ®Google Scholar
• Relling MV, Pui CH, Sandlund JT, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet. 2000;356:285–290.
   PubMed Web of Science ®Google Scholar
• Bertholee D, Maring JG, van Kuilenburg AB. Genotypes affecting the pharmacokinetics of anticancer drugs. Clin Pharmacokinet. 2017;56:317–337.
   PubMed Web of Science ®Google Scholar
• Salerno SN, Burckart GJ, Huang SM, et al. Pediatric drug-drug interaction studies: barriers and opportunities. Clin Pharmacol Ther. 2018;105:1067–1070.
   PubMed Web of Science ®Google Scholar
• Barrett JS, Patel D, Dombrowsky E, et al. Risk assessment of drug interaction potential and concomitant dosing pattern on targeted toxicities in pediatric cancer patients. AAPS J. 2013;15:775–786.
   PubMed Web of Science ®Google Scholar
• Kaul S, Korgenski EK, Ying J, et al. A retrospective analysis of treatment-related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemia. Cancer Med. 2016;5:221–229.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Pediatric Terminology. 2018 [accessed 2018 Nov 27]. Available from: https://www.cancer.gov/research/resources/terminology/pediatric
   Google Scholar
• Meurer S. Mortality risk adjustment methodology for university health system’s clinical data base. 2008 [accessed 2018 Nov 27]. Available from: http://archive.ahrq.gov/professionals/qualitypatient-safety/quality-resources/tools/mortality/Meurer.pdf
   Google Scholar
• CMS. Global Surgery Booklet Medical Learning Network. The Centers for Medicare & Medicaid Services. 2018. ICN 907166.
   Google Scholar
• Rb M. International Nonproprietary Names. 2017 [accessed 2018 Nov 27]. Available from: http://www.who.int/medicines/services/inn/en/
   Google Scholar
• Turner JP, Jamsen KM, Shakib S, et al. Polypharmacy cut-points in older people with cancer: how many medications are too many? Support Care Cancer. 2016;24:1831–1840.
   PubMed Web of Science ®Google Scholar
• Information from PharmGKB.org [internet]. 2019 [accessed 2019 Jan 5]. Available from: https://wwwpharmgkborg/downloads
   Google Scholar
• Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92:414–417.
   PubMed Web of Science ®Google Scholar
• Micallef L, Rodgers P. eulerAPE: drawing area-proportional 3-Venn diagrams using ellipses. PLoS One. 2014;9:e101717.
   PubMed Web of Science ®Google Scholar
• Kastner M, Wilczynski NL, Walker-Dilks C, et al. Age-specific search strategies for Medline. J Med Internet Res. 2006;8:e25.
   PubMed Web of Science ®Google Scholar
• Oladimeji PO, Chen T. PXR: more than just a master xenobiotic receptor. Mol Pharmacol. 2018;93:119–127.
   PubMedGoogle Scholar
• Unguru Y, Bernhardt MB, Berg SL, et al. Chemotherapy and supportive care agents as essential medicines for children with cancer. JAMA Pediatr. 2019;173:477.
   PubMed Web of Science ®Google Scholar
• Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015;33:2949–2962.
   PubMed Web of Science ®Google Scholar
• Bhatt-Mehta V. “Potential” drug-drug interactions and the PICU: should we worry about ICU polypharmacy? Pediatr Crit Care Med. 2016;17:470–472.
   PubMed Web of Science ®Google Scholar
• LeBlanc TW, McNeil MJ, Kamal AH, et al. Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol. 2015;16:e333–e341.
   PubMed Web of Science ®Google Scholar
• Voll ML, Yap KD, Terpstra WE, et al. Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs. Pharm World Sci. 2010;32:575–580.
   PubMedGoogle Scholar
• Stoll P, Kopittke L. Potential drug-drug interactions in hospitalized patients undergoing systemic chemotherapy: a prospective cohort study. Int J Clin Pharm. 2015;37:475–484.
   PubMed Web of Science ®Google Scholar
• Lemachatti J, Leveque D, Beretz L, et al. Potential pharmacokinetic interactions affecting antitumor drug disposition in cancer patients. Anticancer Res. 2009;29:4741–4744.
   PubMed Web of Science ®Google Scholar
• Riechelmann RP, Moreira F, Smaletz Ò, et al. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005;56:286–290.
   PubMed Web of Science ®Google Scholar
• Mora J, Valero M, DiCristina C, et al. Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients. Pediatr Blood Cancer. 2019;66:e27690.
   PubMed Web of Science ®Google Scholar
• Mizuno T, O'Brien MM, Vinks AA. Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediatric patients with acute lymphoblastic leukemia. Eur J Pharm Sci. 2019;128:209–214.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U. Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. Clin Infect Dis. 2012;54:1785–1792.
   PubMed Web of Science ®Google Scholar
• Coutant DE, Kulanthaivel P, Turner PK, et al. Understanding disease-drug interactions in cancer patients: implications for dosing within the therapeutic window. Clin Pharmacol Ther. 2015;98:76–86.
   PubMed Web of Science ®Google Scholar
• Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36:205–216.
   PubMed Web of Science ®Google Scholar
• Le Guellec C, Benz-de Bretagne I, Jonville-Bera AP, et al. A case of severe toxicity during coadministration of vincristine and piperacillin: are drug transporters involved in vincristine hypersensitivity and drug-drug interactions? J Pediatr Hematol Oncol. 2012;34:e341–343.
   PubMed Web of Science ®Google Scholar
• Bahar MA, Setiawan D, Hak E, et al. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. Pharmacogenomics. 2017;18:701–739.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074–D1082.
   PubMed Web of Science ®Google Scholar
• Barbarino JM, Whirl-Carrillo M, Altman RB, et al. PharmGKB: a worldwide resource for pharmacogenomic information. WIREs Syst Biol Med. 2018;10:e1417.
   PubMed Web of Science ®Google Scholar
• Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol. 2004;5:489–496.
   PubMed Web of Science ®Google Scholar
• Hellfritzsch M, Pottegard A, Pedersen AJ, et al. Topical antimycotics for oral candidiasis in warfarin users. Basic Clin Pharmacol Toxicol. 2017;120:368–372.
   PubMed Web of Science ®Google Scholar
• Chung H, Yu KS, Hong KT, et al. A significant influence of metronidazole on busulfan pharmacokinetics: a case report of therapeutic drug monitoring. Ther Drug Monit. 2017;39:208–210.
   PubMed Web of Science ®Google Scholar
• Viergever RF, Rademaker CM, Ghersi D. Pharmacokinetic research in children: an analysis of registered records of clinical trials. BMJ Open. 2011;1:e000221.
   PubMed Web of Science ®Google Scholar
• Cies JJ, Jain J, Kuti JL. Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia. Pediatr Blood Cancer. 2015;62:477–482.
   PubMed Web of Science ®Google Scholar
• Constance JE, Campbell SC, Somani AA, et al. Pharmacokinetics, pharmacodynamics and pharmacogenetics associated with nonsteroidal anti-inflammatory drugs and opioids in pediatric cancer patients. Expert Opin Drug Metab Toxicol. 2017;13:715–724.
   PubMed Web of Science ®Google Scholar
• McAuliffe JJ. Another step toward rational treatment of cancer pain in children…but pharmacokinetic analysis doesn’t tell the whole story. J Pediatr. 1999;135:12–14.
   PubMed Web of Science ®Google Scholar
• Kooijmans EC, Bokenkamp A, Tjahjadi NS, et al. Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev. 2019;3:CD008944.
   PubMedGoogle Scholar
• Sung L, Gamis A, Alonzo TA, et al. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer. 2009;115:1100–1108.
   PubMed Web of Science ®Google Scholar
• Kavcic M, Fisher BT, Li Y, et al. Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States. Cancer. 2013;119:1916–1923.
   PubMed Web of Science ®Google Scholar
• Meeker ND, Yang JJ, Schiffman JD. Pharmacogenomics of pediatric acute lymphoblastic leukemia. Expert Opin Pharmacother. 2010;11:1621–1632.
   PubMed Web of Science ®Google Scholar